Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

A 23-year-old has been using 0.5mg Dutasteride and 5mg oral Minoxidil daily for two years, but their hair has thinned considerably. Suggestions include increasing the Dutasteride dose, adding Finasteride, or considering a hair transplant.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

Hair loss is likely due to male pattern baldness, not vitamin D deficiency. Taking 60k vitamin D tablets weekly is not recommended; 2k per day is sufficient.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

The user experienced significant hair regrowth using 1.25mg finasteride, 5mg oral minoxidil, ketoconazole shampoo, and scalp massages, with the main side effect being excessive body hair growth. They are surprised by the results, as even doctors are shocked by the effectiveness, and they attribute their success to genetics.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.

A user on Finasteride for 7-8 years reported unexpectedly high testosterone levels despite expecting lower levels due to age, with discussions on the impact of SHBG and suggestions to use boron to lower SHBG. Another user noted that Dutasteride significantly increased their testosterone and free testosterone levels.

Calculating the correct dosage of vitamin D from a 60,000 IU bottle using a dropper. The user is advised to take 0.05 ml for 600 IU, but struggles with finding a suitable supplement without additional ingredients like omega 3 or calcium.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A 25-year-old male is concerned about his blood test results, particularly the low percentage of free testosterone, and is questioning whether starting finasteride for hair loss might worsen this issue. He also notes a slight vitamin D deficiency and lack of sleep before the test.

A 23-year-old male has been using 1.1mg finasteride and 5mg oral minoxidil for 4 months and is questioning if he has experienced hair regrowth. He reports some thickening of arm and facial hair but no serious side effects.

The user has been using finasteride, vitamin D3, and zinc for 5.5 months and had a hair transplant 3.5 months ago, focusing on the hairline and crown. Some users see subtle improvements in hair density, suggesting adding minoxidil for better results.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

The user added dutasteride once a week for three months and shared blood work results, noting low vitamin D. Another user mentioned experiencing hair thinning while on the same treatment.

The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.

The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.

PP405 is expected to work for hair regrowth by reactivating stem cells in hair follicles, with FDA approval anticipated in 2027-28. Users express both optimism and skepticism about its effectiveness and the lengthy approval process.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A user is experiencing hair thinning and is using a peptide with oleanic acid as a DHT blocker, along with minoxidil, while waiting for topical finasteride. They plan to use a combination of minoxidil, finasteride, dermastamp, ketoconazole, and scalp massages, but are advised to stick to proven treatments like finasteride and minoxidil.

The conversation discusses hair regrowth after 100 days using 5mg Minoxidil and 0.5mg Dutasteride, focusing on changes in the temples and hairline. Users debate the effectiveness due to inconsistent photo comparisons.

A user reversed hair loss using 0.5 mg of dutasteride daily without side effects. Others noted hair thickening but questioned the absence of minoxidil use.

A 30-year-old man experienced significant hair regrowth and improved libido after using finasteride and dutasteride for androgenetic alopecia, with no adverse effects. He plans to reduce dutasteride dosage when trying to conceive and has been using topical minoxidil since 2015.

Finasteride has no effect on the user's estradiol levels, and body fat may influence aromatization. The user is on testosterone replacement therapy and uses everyday injections to manage high RBC count, with plans to measure DHT, DHEA-S, and pregnenolone levels.